{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-036339","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2022-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.708639+00:00","generated_at":"2026-06-23T04:52:07.692869+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Galectin Therapeutics reports positive DSMB outcome for NAVIGATE study of belapectin in NASH cirrhosis","bullets":["Second DSMB meeting recommends study continue as designed without modifications.","NAVIGATE is a seamless adaptive Phase 2b/3 trial of belapectin for primary prevention of esophageal varices in NASH cirrhosis.","Enrollment: 258 patients randomized; 74 in screening; full enrollment expected around year-end 2022.","DSMB confirms belapectin appears safe and well tolerated in fragile cirrhotic patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-036339","json":"https://secwatch.observer/filing/0001140361-22-036339.json","markdown":"https://secwatch.observer/filing/0001140361-22-036339.md","text":"https://secwatch.observer/filing/0001140361-22-036339.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036122036339/0001140361-22-036339-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036122036339/brhc10042729_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:52:07.692869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}